WellPoint sanctions might be indicative of deeper oversight problems in Medicare.
"Clearly, computer systems need to be updated, but the problem here stems from the push toward private delivery mechanisms, and, within that push, the emphasis on providing unlimited choices rather than on quality of choice," she says.
She believes patients wouldn't have to worry about such problems if the drug benefit were administered by the traditional Medicare program.
WellPoint has 1.9 million members in its Part D plan and 472,000 in its private Medicare health plans.
In its letter to the company, CMS cited the insurer's "longstanding and persistent" failure to meet Medicare's requirements, resulting in a "serious threat" to the health of its members. While the sanctions were prompted by a flurry of consumer complaints over a two-week period, the computer problems had been going on for months. In fact, WellPoint had been providing CMS with details of its plans to fix the problems and even hired a third-party company to report on its progress.
ACTION SURPRISING
Because of those regular interactions with the agency, WellPoint executives were taken aback by CMS' sanctions. "Since we have been meeting with CMS on a regular basis regarding our remediation process, we were surprised by this recent action," an emailed statement said. "We have made significant progress in addressing these issues."
While some believe the harshness of WellPoint's punishment is a sign of tougher and more vigilant government enforcement, others disagree. The fact that it took CMS months to sanction WellPoint is indicative of another problem: not enough oversight and enforcement of Medicare's requirements.
"We have been concerned that, because CMS has seen its role more as a partner than as a regulator, [the government] has not acted efficiently and sufficiently when plans fail to comply with rules," Gottlich says. "We have had other experiences of plan sponsors being sanctioned by CMS, only to engage in similar activity. Those of us who follow it see this as a black eye for the entire Medicare Part D program, as will the [WellPoint] beneficiaries who couldn't get their medicine.
"I don't think the public will have the same perception, however. CMS did a good job of portraying this as finding problems, hearing beneficiary complaints during the first nine days of the year, and then taking action," she says.
A Conversation With Greg Baker, RPh, CEO of AffirmedRx
March 31st 2024Greg Baker, CEO of AffirmedRx, describes his early career, shares some of his critical opinions about the pharmacy benefit management (PBM) industry and how, in his view, his company is offering a better alternative.
Read More
David Calabrese of OptumRx Talks New Role, Market Insulin Prices and Other Topics 'On His Mind'
April 13th 2023In this month’s episode of the "What's On Your Mind podcast," Peter Wehrwein, managing editor of MHE connects with the now Chief Clinical Officer of OptumRx Integrated Pharmacies, David Calabrese. In this conversation, David touches on his transition in January as OptumRx’s former chief pharmacy officer and market president of health plans and PBMs to his new role as Chief Clinical Officer where he now focuses more on things such as specialty pharmacy to home delivery — with an overall goal of creating whole-patient care. Throughout the conversation, Calabrese also touched on the market’s hot topic of insulin prices and behavioral health services within the OptumRx community, among other topics.
Listen
Florida Gets the OK. But Will Drug Importation from Canada Actually Happen?
March 5th 2024Canadian health officials warn that maintaining a drug supply for Canadians is their priority. The staunch opposition of the U.S. pharmaceutical industry may also be an obstacle to imports from north of the border.
Read More
Briana Contreras, editor of Managed Healthcare Executive, spoke with Nancy Lurker, CEO and president of EyePoint Pharmaceuticals. Nancy shared a bit about EyePoint and how the organization’s innovative therapies are addressing patient needs through eye care, and most importantly, she addressed C-Suite positions like the CEO role. Nancy shared advice for those seeking to reach the CEO level, especially toward women in healthcare and other roles, and what it takes to run a biopharma company.
Listen
What Payers Need to Know As Retail Pharmacies Move Into Primary Care
September 6th 2023Healthcare beyond the doors of the doctor’s office has the potential to offer more care to more people. But payers need to think about how to ensure that care is consistent. Regardless of the setting, care decisions must be based on evidence-based content and supported with strong patient education.
Read More